Diabetes Dialogue: What Teplizumab Means for Type 1 Diabetes

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, break down what the approval of teplizumab means for type 1 diabetes. During the episode, hosts take a deep dive into type 1 diabetes staging and hypothesize around the role of CDCES in educating primary care and other specialties to optimize the potential of teplizumab.

Episode metadata supplied by the publisher feed · Published Nov 17, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Diabetes Dialogue: What Teplizumab Means for Type 1 Diabetes

0:00 27:10

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 27 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on November 17, 2022.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!